Objective-To investigate the reactivity with TIA-1 and TIA-2, two monoclonal antibodies that recognise, respectively, granular structures in T lymphocytes and the T cell receptor chain in cells from a variety of T cell disorders. Methods-Cytoplasmic staining with TIA-1 and TIA-2 was carried out by the immunoalkaline phosphatase anti-alkaline phosphatase technique in 67 cases with a T cell disorder: 31 large granular lymphocyte (LGL) leukaemia, nine T-prolymphocytic leukaemia (T-PLL), five Sezary syndrome, four peripheral T cell lymphoma (PTCL), 13 T cell lymphocytosis, and five T-acute lymphoblastic leukaemia (T-ALL). All had over 75% abnormal T cells which were CD2+, CD3+, CD5+, CD7+, and negative with B cell markers.
Results-TIA-1 was positive in 77% cases of LGL leukaemia and half of the PTCL and T-ALL, whereas it was negative in all Sezary syndrome and most T-PLL (8/9) and reactive T-lymphocytosis (10/13) . In LGL leukaemia, TIA-1 was positive irrespective of the membrane phenotype, whether CD8 +, CD4-or CD4 +, CD8-, and was more often positive in cases where cells were CD16+, CD56+, or CD57+. TIA-2 was positive in 60% of cases encompassing all diagnostic types of T cell disorder. There was no correlation between TIA-2 expression and that of other T cell markers, activation antigens, and natural killer markers. Conclusions-The pattern of TIA-1 expression in T cell malignancies may help in the differential diagnosis among LGL leukaemia (high expression), T cell lymphocytosis and other T cell diseases (low expression). As We have studied the reactivity of TIA-1 and TIA-2 in T-lymphoproliferative disorders and T cell lymphocytosis to investigate their possible role in differential diagnosis, in defining more precisely the cell nature of these diseases, and disclosing immunophenotypes which can be exploited for the detection of minimal residual disease.
Methods

PATIENTS
Peripheral blood mononuclear cells from 54 patients with a T cell malignancy and 13 with T cell lymphocytosis have been analysed. These 12 The reactivity with TIA-1 and TIA-2 was evaluated by the APAAP technique" using a 1 Figure 1 Lymphocytes from a case with LGL leukaemia strongly positive with TIA-1. Note a negative cell (APAAP technique).
in 1000 dilution for TIA-l and a 1 in 50 dilution for TIA-2 from a starting concentration as recommended by the manufacturers. Some samples were also investigated by flow cytometry after fixation and permeabilisation of the cell membrane. A case was considered positive with TIA-1 or TIA-2 when more than 30% cells reacted with either antibody.
The monoclonal antibodies TIA-1 and TIA-2 were commercially available from Coulter clone and both are mouse IgGI ascites fluid.
Results
IMMUNOLOGICAL MARKERS
The cells in the cases studied were positive with one or more T cell markers as follows: CD2 (96%), CD3 (91%), CD5 (89%), and CD7 (78%), and they were negative with B cell markers. TdT and/or CD1a were negative in all but the five cases of T-ALL which were TdT + and two which were CD 1 a +. Cells from most LGL leukaemias were CD8 +, CD4 -whereas a CD4 +, CD8 -phenotype was more frequent in Sezary syndrome and T cell lymphocytosis, and coexpression of CD4 and CD8 was more frequent in T-PLL (table 2) .
Expression of NK associated markers was more common in LGL leukaemia, namely CD11b in 17/27 (63%) of cases, CD16 in 8/ 
LGL leukaemia large granular lymphocyte leukaemia; T-PLL= T-prolymphocytic leukaemia; PTCL peripheral T-cell lymphoma; T-ALL=T-acute lymphoblastic leukaemia. Table 4 shows the correlation between the expression of TIA-1 and a CD8 + or CD4 + phenotype. Although it would appear that TIA-1 was more frequently positive in cases with CD8 +, CD4 -and CD8 -, CD4 -phenotypes, this was because most cases with these markers corresponded to LGL leukaemia. When considering each disease category, particularly LGL leukaemia, TIA-1 was positive regardless of the marker profile, albeit slightly more often in cases where cells were CD8 +. There was no correlation between TIA-2 expression according to the reactivity with CD4 and CD8, nor with that of other T cell markers, particularly membrane CD3 and T cell activation markers (data not shown). Table 5 shows the correlation between the reactivity with TIA-1 and TIA-2 and the expression of NK markers in LGL leukaemia. LGL leukaemnia = large granular lymphocyte leukaemia; T-PLL=T-prolymphocytic leukaemia; PTCL=peripheral T-cell lymphoma; T-ALL=T-acute lymphoblastic leukaemia. We have shown here that TIA-1 is expressed in cells from the majority of cases of LGL leukaemia and, as a rule, is negative in the other T cell diseases. Although cells from some PTCL and T-ALL were TIA-1 positive, the number of cases was too small to draw conclusions. Cases with reactive T cell lymphocytosis which could be confused with LGL leukaemia were less often TIA-1 positive. The fact that TIA-1 expression did not correlate with the cells being CD8 + or CD4 + but rather with granular lymphocyte morphology suggests that it might possibly be ofvalue in the differential diagnosis between LGL leukaemia with Sezary syndrome and T-PLL, as cells from several T-PLL and Sezary syndrome cases had a CD8 +, CD4-or a CD8 +, CD4 + phenotype, the former phenotype being common in LGL leukaemia.
Our results suggest that most cases of LGL leukaemia arise from the expansion of CD8 +, TIA-1 + lymphocytes with a possible cytotoxic function. Six cases (four LGL leukaemia, one PTCL, and one T-ALL) who had a CD4 -, CD8 -phenotype stained with TIA-1 but none had a pure NK phenotype profile and all but one were CD3 +; the CD3 negative case was positive with other T cell markers. Probably none of them represented a proliferation of TIA-1 positive NK cells.
The pattern of staining with TIA-2 was more variable, without evidence of an association with a particular disease. A proportion of cases were TIA-2 negative and thus lacked the TCR-4 chain which plays a key role as a signal transducing molecule during activation of T and NK cells. This suggests indirectly an impaired immunological function for such leukaemic cells. Indeed, a decrease in the cytotoxic and proliferative response to signalling through the TCR has been shown in mice lymphocytes which lack the TCR-4 chain or express it poorly.'5 The lack of TCR-4 in leukaemic T cells was unrelated to the expression of CD3 or CD1 6, molecules to which the TCR-; chain is associated in T and NK cells, respectively. The lack of or weak expression of TIA-2 is also found in tumour infiltrating lymphocytes in mice and humans" 16 and it has recently been reported in non-neoplastic T cells in a case of B cell non-Hodgkin's lymphoma.10 Its absence in some T cell malignancies might be useful in monitoring response to treatment.
In conclusion, we report the spectrum of reactivity of two new monoclonal antibodies, TIA-1 and TIA-2, in a variety of T cell disorders. We have shown that TIA-1 is a useful marker for LGL leukaemia and that TIA-2 might be helpful in monitoring the disease status in patients whose cells are negative for this monoclonal antibody.
